IC BIOSOLUTIONS is now a member of Atlanpole Biotherapies, the health competitiveness cluster supporting innovation in biotherapies, bioproduction, pharma, medical technologies and digital health.
This membership represents an important step in the company’s development and reflects the relevance of its positioning within the HealthTech and biotherapy ecosystem.
Through its acellular secretome-based therapeutic platform, IC BIOSOLUTIONS is developing a new class of investigational therapies, with an initial focus on equine joint-related diseases and broader potential applications across species.
Joining Atlanpole Biotherapies will support IC BIOSOLUTIONS in strengthening its scientific, industrial and regulatory network, while contributing to the emergence of new therapeutic approaches.